CDK12 and mismatch repair cancer syndrome 1: A study to assess the activity and efficacy ofpembrolizumab in participants with progressive metastatic castration-resistantprostate cancer, characterized by a mismatch repair deficiency orbiallelic CDK12 inactivation.